Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
Leendert Trouw benoemd tot hoogleraar Complementbiologie en -therapie
feb 2023 | Immuuntherapie, RA, Tuberculose